Nitric oxide

Vasodilator — RESPIRATORY SYSTEM

Key facts

Nitric oxide is a drug in the Vasodilator class catalogued in DrugCentral. It was first approved by the FDA in 1999. DrugCentral lists 1 molecular target, including GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3. Recorded indications include Persistent pulmonary hypertension of the newborn and Pulmonary hypertension.

• Drug class: Vasodilator.
• Molecular targets: GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3 (1 listed in DrugCentral).
• Indications: Persistent pulmonary hypertension of the newborn and Pulmonary hypertension.
• ATC code: R07AX01 (Other respiratory system products).
• Molecular formula: NO; molecular weight 30.01 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Persistent pulmonary hypertension of the newborn
• Pulmonary hypertension

Contraindications (3)

• Congenital Heart Defect Requiring Open Patent Ductus Arteriosus
• Left heart failure
• Methemoglobinemia

Mechanism & targets

• Established pharmacologic class: Vasodilator

Molecular targets (1)

Target	Gene	Action	Activity
Soluble guanylate cyclase	GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3	activator	—

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2001-08-01	EMA	—	LINDE HEALTHCARE AB
1999-12-23	FDA	—	INO	Yes

ATC classification

ATC code	Therapeutic hierarchy
R07AX01	RESPIRATORY SYSTEM › OTHER RESPIRATORY SYSTEM PRODUCTS › OTHER RESPIRATORY SYSTEM PRODUCTS › Other respiratory system products

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
No adverse event	2763.0
Device malfunction	2453.9
Device issue	1112.6
Underdose	663.6
Device delivery system issue	566.1
Product use issue	533.4
Device failure	525.0
Oxygen saturation decreased	407.3
Death	321.3
Pulmonary haemorrhage	240.5
Pulmonary hypertension	193.5
Pulmonary hypertensive crisis	182.9

Chemical structure

• Molecular formula: NO
• Molecular weight: 30.01 g/mol
• CAS number: 10102-43-9
• InChIKey: MWUXSHHQAYIFBG-UHFFFAOYSA-N
• PubChem CID: 145068

[N]=O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nitric oxide used for?

DrugCentral lists the following indications for Nitric oxide: Persistent pulmonary hypertension of the newborn and Pulmonary hypertension.

How does Nitric oxide work?

Its molecular targets in DrugCentral include GUCY1B2|GUCY1A2|GUCY1A3|GUCY1B3 (activator).

When was Nitric oxide first approved?

Nitric oxide was first approved by the FDA in 1999.

What drug class does Nitric oxide belong to?

Nitric oxide is in the Vasodilator class.

What is the chemical formula of Nitric oxide?

Nitric oxide has the molecular formula NO and a molecular weight of 30.01 g/mol.

Sources

• DrugCentral drug card 1948 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200689 — compound record and bioactivity
• PubChem CID 145068 — chemical identifiers
• DrugBank DB00435 — drug record
• FDA UNII 31C4KY9ESH — substance identity
• DailyMed: FDA labels for Nitric oxide — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.